A Phase 1 interventional study of ZD6474 (vandetanib) 100mg and pemetrexed in Carcinoma, Non-Small Cell Lung and Lung Cancer, sponsored by Genzyme, a Sanofi Company. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-25.
Sponsored by Genzyme, a Sanofi Company · Phase 1, Interventional, and Treatment
The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets) to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than the chemotherapy alone.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 21 is below the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Genzyme, a Sanofi Company is the lead sponsor of 303 studies on the registry; 5 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 19 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: ZD6474 (vandetanib) 100mg · Drug: pemetrexed
Drug: pemetrexed · Drug: ZD6474 (vandetanib) 300mg
once daily oral tablet
Also known as: ZACTIMA™
intravenous infusion
Also known as: Alimta®
Also known as: ZACTIMA™
To establish the safety & tolerability of ZD6474 when administered in combination w/Pemetrexed (Alimta) to patients w/locally advanced or metastatic NSCLC after failure of prior chemo, by assessment of AEs, vital signs, lab, ECG and physical exam.
Time frame: assessed at each visit
To investigate the pharmacokinetics of ZD6474 and Pemetrexed when given in combination to patients with locally advanced or metastatic NSCLC after failure of prior chemotherapy, by assessment of appropriate pharmacokinetic (PK) parameters.
Time frame: assessed at each visit
No study locations are listed for this record.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genzyme, a Sanofi Company